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616Background: Pediatric ventricular assist devices may be superior to extracorporeal membrane oxygenation in
some respects, especially for medium- and long-term cardiac support. We present our nearly 20-year experience
with pediatric ventricular assist devices.
Methods: Between 1990 and April 2009, Berlin Heart EXCOR (Berlin Heart AG, Berlin, Germany) was im-
planted in 94 children. Patients were compared according to period of treatment: group I, implantation between
1990 and 2001 (n ¼ 45), and group II, implantation since 2002 (n ¼ 49).
Results: Preoperative serum creatinine (1.2 vs 0.7 mg/dL, P ¼ .002) and bilirubin (1.5 vs 1 mg/dL, P ¼ .002)
were lower in period II, and fewer patients were artificially ventilated before surgery (26 vs 13, P ¼ .002). In
period I, more patients were supported with biventricular assist devices (64% vs 22.5%, P<.001). Median
time on support was shorter in period I (10 vs 40 days, P<.001). Success (weaning from system or heart trans-
plant) was achieved in 49% and 69%, respectively (P ¼ .043). Whereas in period I 17% of children younger
than 1 year were discharged home after transplant or weaning, rate during period II was 93% (P<.001), in par-
ticular because of improvement in discharge rate of patients with postcardiotomy heart failure (13% vs 50%).
Rates of pump exchange for thrombus formation were 0.029/d in period I and 0.014/d in period II (P ¼ 0.003).
Conclusions: Recent results show significant improvements in survival and discharge rate, especially for chil-
dren younger than 1 year. Pediatric Berlin Heart EXCOR ventricular assist device may provide a safe mechan-
ical support strategy in children with cardiogenic shock. (J Thorac Cardiovasc Surg 2011;141:616-23)Supplemental material is available online.
For support of the failing heart in children, modifications of
the original heart–lung machine circuit, such as extracorpo-
real membrane oxygenation (ECMO)1-3 and extracorporeal
centrifugal pumps,4 have been widely used since the devel-
opment of pediatric cardiac surgery. Pediatric-size pneu-
matically driven extracorporeal assist devices for infants
and small children were introduced into clinical practice
in 1992. The development of such miniaturized pump sys-
tems5 followed the experience of the first reported pediatric
case, in which an 8-year-old patient was supported with an
adult-size ventricular assist device (VAD) until later trans-
plant at our institution.6 Although pumps for neonates and
infants of 10-mL pump volume then became available, ineutsches Herzzentrum, Berlin, Germany.
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Until 1998, no patient younger than 1 year was discharged
home after such treatment at our institution.7 Since then,
several improvements have been introduced with regard
to system design, postoperative management, and, most im-
portantly, earlier decision making in favor of pump implan-
tation before irreversible shock has set in. We present our
experience since 2002 (period II) in comparison with the
earlier period of 1990 to 2001 (period I).MATERIALS AND METHODS
This analysis is a retrospective study of the use of Conformite Euro-
peenne–certified Berlin Heart EXCOR VADs (Berlin Heart AG, Berlin,
Germany). Under German law, the retrospective data analysis did not re-
quire approval by the ethics committee (in accordance with the Helsinki
Declaration of Human Rights). Informed consent to placement of the de-
vice was obtained from the parents of all patients.
Patients
Since 1990, and as of April 1, 2009, Berlin Heart EXCOR systems have
been implanted in 94 patients younger than 18 years who had inotrope-
dependent end-stage heart failure, were switched from ECMO support,
or had postcardiotomy syndrome. The patients were divided into groups ac-
cording to the period of treatment: period I represented implantation be-
tween 1990 and the end of 2001 (n ¼ 45), and period II represented
implantation between the beginning of 2002 and April 1, 2009 (n ¼ 49).
The treatment periods were chosen because after 2001 there were no fur-
ther modifications of the Berlin Heart pediatric system (Carmeda heparinery c March 2011
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BNP ¼ B-type natriuretic peptide
BVAD ¼ biventricular assist device
ECMO ¼ extracorporeal membrane oxygenation
LVAD ¼ left ventricular assist device
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Dcoating [Carmeda AB, Upplands V€asby, Sweden], improvements in the
aortic cannulas), of implantation techniques (left apical vs atrial cannula-
tion; Figure 1), or of perioperative management (anticoagulation). In addi-
tion, several subgroups were analyzed according to age, diagnosis, and
mode of support (univentricular vs biventricular). Treatment was consid-
ered successful when the patient survived until a heart transplant was per-
formed, the patient was weaned from the system, which was explanted, or
the patient was discharged home.
The Berlin Heart System
The Berlin Heart EXCORVAD consists of a paracorporeal, pneumatic,
compressor-operated diaphragm pump with polyurethane valves (stroke
volumes 10, 25, and 30 mL). The larger pumps (50, 60, and 80 mL)
were equipped with mechanical valves (Sorin S.p.A., Milan, Italy). In all
pumps, silicone cannulas were used. The fairly large Ikus driving unit (Ber-
lin Heart) may be used with all pumps and in all situations; when driving
pressures lower than 250 mm Hg were required, the EXCOR mobile driv-
ing unit (Berlin Heart) was used with pumps of 50, 60, or 80 mL. The blood
pumps were available in both periods with volumes of 10, 25, 30, 50, 60,
and 80 mL. In period I, in addition, modified pumps with 12- and 15-mL
stroke volumes were applied in some cases. The system has been described
in detail previously.8-10 The pediatric EXCOR device has not been
approved by the U.S. Food and Drug Administration for use in the
United States and is limited to investigational use under an approved
investigational device exemption. The device may also be assessed under
the compassionate use regulations, with Food and Drug Administration
approval granted on a case by case basis.
Criteria for VAD Implantation
Criteria for VAD implantation changedwith time, tending toward earlier
implantation before significantmultiorgan failure occurs or after a few daysFIGURE 1. Implantation of pediatric Berlin Heart VAD in left and biventricu
ventricle (B). Left apical implantation is preferred because it provides better
mode (C).
The Journal of Thoracic and Caof ECMO to avoid coagulation disorders and infection. The criteria applied
were as follows: rapid deterioration of the circulation (cardiac index<2.0 L
min $ m2) with dependence on inotropes, especially epinephrine; critical
peripheral perfusion with development of metabolic acidosis andmixed ve-
nous saturation less than 40%; signs of beginning renal, hepatic, and respi-
ratory failure (patient on respirator with mounting inspired oxygen
fraction); and, most recently, high or rapidly increasing B-type natriuretic
peptide (BNP) or N-terminal pro-BNP level. There are no defined cutoff
values; the decision was influenced by the rate of clinical deterioration.
Anticoagulation During Device Support
The current strategy at our institution is as follows: In standard cases, an-
ticoagulation is performedwith unfractionated heparin. The effect is closely
monitored (2–4 times daily, depending on the clinical situation and the re-
sponse of the coagulation system of the patient) by measurement of acti-
vated partial thromboplastin time with a target of 60 to 80 seconds.
Thromboelastography helps to identify the coagulation status and impact
of heparin. Antithrombin III should also be closely monitored and
substituted if the level falls below 70%. We have continuously improved
our anticoagulationmanagement, and since 2007 children remaining in hos-
pital with VAD support have received low–molecular weight heparin for
long-term anticoagulation undermonitoring of anti-Xa activity, as described
by Ghez and colleagues.11 The target anti-Xa activity is set at between 1.0
and 1.2 IU/mL. After treatment with acetylsalicylic acid and dipyridamole
has been initiated (after the start of oral feeding and the removal of chest
tubes and in a dose adjusted to patient weight), platelet aggregation tests
are performed at least weekly, with target activation of 30%.12 In patients
with heparin-induced thrombocytopenia type II, L-hirudin or argatroban is
used.13 Adolescents who are discharged home with VAD support receive
phenprocoumon with a target international normalized ratio of 3 to 3.5.Weaning Criteria
Weaning was considered for patients with continuous improvement in
myocardial function and appropriate wall thickness changes, as measured
by daily echocardiography in all patients. Pulmonary pressure was moni-
tored in larger patients by pulmonary catheter and in smaller children by
echocardiography. No dobutamine stress echocardiography was per-
formed. The pump flow was then decreased, and blood pressure and ven-
tricular filling were observed. Echocardiographic studies (conventional
echocardiography plus tissue Doppler and strain imaging) were performed
during a pump stop lasting not more than 30 minutes, while an additional
heparin dose was administered (70–100 IU/kg body weight), and the pumplar modes. Inflow cannula is implanted into left atrium (A) or apex of left
unloading of left ventricle. Implantation is also possible in biventricular
rdiovascular Surgery c Volume 141, Number 3 617
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Dsystem was operated manually (1–2 times every 30 seconds) to avoid
thrombus formation.
Weaning was decided on and performed when, during repeated pump
stops (usually 3–4) without any inotropic support, left ventricular ejection
fraction remained stable at greater than 45%, left ventricular end-diastolic
diameter also remained stable at around the 97% percentile of age-related
index value, and, if appropriate, mitral valve regurgitation did not worsen.
Additionally, stable central venous saturation and low pulmonary arterial
pressure (estimated by echocardiography) during pump stops were consid-
ered to be good prognostic parameters, as was normalization of the level of
BNP or N-terminal pro-BNP during the entire weaning period. In some
cases of suspected myocarditis or unclear diagnosis, an additional biopsy
was helpful.
The weaning protocol was the same for different pump sizes. Weaning
was considered successful if the patient had stable myocardial function
throughout the first year after device explantation.
Discharge Home With Berlin Heart System
Small children dependent on the stationary Ikus driver were kept in the
hospital with a continuous heparin infusion (except patients treated with
low–molecular weight heparin). Discharge home with VAD support is al-
lowed in Germany, and older children for whom the portable EXCOR
driver could be operated were discharged home whenever possible, receiv-
ing anticoagulation with vitamin K antagonist (monitoredwith home use of
an international normalized ratio measurement device) and acetylsalicylic
acid (monitored by platelet aggregation tests performed at ambulatory
visits). These children went to school with the device. Details of the outpa-
tient management have been described by Drews and associates14 from our
working group.
Statistical Analysis
The statistical analysis was performed with the SPSS version 12.1 soft-
ware package forWindows (SPSS Inc, an IBMCompany, Chicago, Ill). For
continuous data, means and SDs or medians and ranges were calculated.
Categoric data are reported as relative frequencies and percentages. The
Mann–Whitney t test or c2 test was applied to test differences between
treatment periods. A cumulative sum plot was constructed to show the im-
pact of the various changes on mortality (Figure E1).
RESULTS
The preoperative data are shown in Table 1. There were
no statistically significant differences in sex, age, or weightTABLE 1. Preoperative patient data and type and duration of support
Preoperative data
Period I
(1990–2001, n
Sex (male/female) 24:21
Age (y, median and range) 7 (0–17)
Weight (kg, median and range) 22 (2.2–11
Cardiopulmonary resuscitation (no.) 20
Ventilator (no.) 26
Extracorporeal membrane oxygenation (no.) 2
Serum creatinine (mg/dL, median and range) 1.19 (0.2–3.
Serum bilirubin (mg/dL, median and range) 1.53 (0.4–13
Type of support (no.)
Left ventricular 15
Biventricular 30
Right ventricular 0
Time on support (d, median and range) 10 (0–111
NS, Not significant.
618 The Journal of Thoracic and Cardiovascular Surgbetween the study periods. In the early period, more patients
received implantation during mechanical ventilation or af-
ter cardiopulmonary resuscitation. This and the elevated se-
rum creatinine reflect the fact that patients in the earlier
period were sicker at the time of implantation.
There were fewer biventricular assist devices (BVADs)
implanted in the later treatment period (64% vs 22.5%,
P<.001), in favor of more left VADs (LVADs; Figure 1).
The median duration of VAD support was significantly
shorter in period I than in period II (10 vs 40 days, P<.001).Diagnoses Before VAD Implantation
Table 2 shows the diagnoses in patients who underwent
VAD implantation. The largest cohort represents patients
with dilated cardiomyopathy and endomyocardial fibrosis,
with increasing numbers in the later period (17, 38%, vs
29, 59%, P ¼ .038). The next largest population was pa-
tients with viral myocarditis, with fewer children treated
in period II (10, 22%, vs 6, 12%). The proportions of pa-
tients with decompensated congenital heart defects was
similar in the two periods (9, 20%, vs 6, 12%); there
were 4 patients late after Senning or Mustard procedure in
period I but none in period II (Table E1). The proportion
of patients requiring VAD after cardiac surgery decreased
slightly in the later period (8, 18%, vs 6, 12%, difference
not significant). Acute graft failure was a reason for VAD
implantation in 1 child in the earlier period and in 2 in the
later period. The outcome related to diagnosis in the two
time periods is given in Figure 2, B.Outcome
There were no cases of fatal technical failure of the de-
vice, such as malfunction of the pump components or driv-
ing system, in either treatment period.
The outcomes in period I (45 patients) and period II (49
patients) were weaning (5, 11%, vs 11, 22.5%, P ¼ .14),¼ 45)
Period II
(2002–2009, n ¼ 49) P value
25:24 NS
6 (0–17) NS
5) 19 (3.6–80) NS
14 NS
13 .002
7 NS
01) 0.7 (1.2–3.96) .002
.28) 1 (0.17–7.14) NS
37 <.001
11
1
) 40 (0–420) < .001
ery c March 2011
TABLE 2. Diagnosis before implantation of ventricular assist device
Period I
(1990–2001,
n ¼ 45)
Period II
(2002–2009,
n ¼ 49)
Cardiomyopathy 17 29
Dilative 16 24
Toxic 1 1
Restrictive — 3
Myocarditis 10 6
End-stage congenital heart disease 8 6
Postcardiotomy heart failure 9 6
Graft failure after heart transplant 1 2
Data represent number of patients.
FIGURE 2. A, Survivals in different age categories in both periods. B,
Hospital discharge rates for different indications for VAD support in
both treatment periods. Note significant improvement for cardiomyopathy
and postcardiotomy heart failure in second period. DCMP, dilated cardio-
myopathy;CHD, congenital heart disease; post-CPB, postcardiotomy heart
failure.
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(23, 51%, vs 14, 29%, P¼ .043); 1 patient in period II was
still receiving support. Seventeen (38%) patients were extu-
bated while supported by the device during period I and 39
(80%) during period II (P ¼ .063). In the early period, 2 of
12 of the infants younger than 1 year (17%) were success-
fully treated, whereas in the later period this proportion in-
creased to 14 of 15 (93%, P< .001). Treatment of the
children aged between 1 and 8 years was successful in
64% of cases in the earlier period and 40% in the later pe-
riod, and treatment of the children older than 8 years was
successful in 59% and 67% of cases in periods I and II, re-
spectively (Figure 2, A). The difference in outcome was not
statistically significant.
According to the preoperative diagnosis, there was
a 3-fold increase in the discharge rate in period II in patients
with postcardiotomy heart failure, although statistical sig-
nificance was not reached (13% vs 50%, P ¼ .12;
Figure 2, B). See also the cumulative sum plot (Figure E1).
Weaning
Sixteen patients were weaned from the VAD. Most of
these children had myocarditis (n¼ 7), 3 patients were suc-
cessfully weaned after correction of congenital heart dis-
ease, 3 had dilated cardiomyopathy, 1 had noncompaction
myocardium, 1 had decompensated heart failure with Eb-
stein anomaly, and 1 had acute graft failure. There was 1
early death immediately after weaning and 1 at 2.5 years
later. One patient underwent heart transplant during
follow-up; no further recurrence of heart failure was noted.
The data are presented in Table 3. There were no long-term
complications after removal of the left ventricular cannula.
The incision of the apex of the left ventricle does not, in our
opinion, cause future ventricular arrhythmias or impair left
ventricular function as long as injury of the main coronary
arteries is avoided.
Bridge to Heart Transplant
In period I 17 children (38%) and in period II 40 children
(82%) were bridged to heart transplant with a VAD. In theThe Journal of Thoracic and Casame total study period, a total of 156 pediatric transplants
were performed at our institution. There was no difference
in long-term survival between children with primary trans-
plants and children bridged to heart transplant by VAD. The
Kaplan–Meier survival data showed no significant differ-
ences in survival between the 2 groups (Figure E2).Complications
In the earlier period 14 re-explorations for bleeding were
necessary in 10 patients (22%), compared with 11 in 11 pa-
tients (22%) in the later period. In the earlier period 25
pumps were exchanged in 13 patients, and in the later pe-
riod 46 pumps were exchanged in 19 patients. The pump ex-
change rate of 0.029 per day in period I was reduced to
0.014 per day in period II (P ¼ .003). In the second period,
however, 12 pump exchanges were performed during
a 3-month period in a single patient with heparin-induced
thrombocytopenia type II (for calculations, 1 day of
BVAD support was counted as 1 pump day). There were 3
cases of cerebral vascular accident resulting in fatality or re-
sidual deficit in period I (cumulative days on support 869),rdiovascular Surgery c Volume 141, Number 3 619
TABLE 3. Patients weaned from ventricular assist device
Case Age (y) Weight (kg) Diagnosis Pumps Support time (d) Outcome
1 5 16 Myocarditis 30/25 22 Weaned, alive
2 6 23 Myocarditis 30/25 11 Weaned, death 2.5 y later
3 1 10 Myocarditis 30/25 11 Weaned, alive
4 1 9 Myocarditis 30/25 10 Weaned, alive
5 14 37 DCMP 60/— 22 Weaned, alive
6 4 17 Ebstein 30/25 17 Bidirectional caval pulmonary
anastomosis, tricuspid valve repair
7 0.4 4 CAVSD 10/— 6 Weaned, later HTx, alive
8 0.3 5 ALCAPA 10/— 11 Weaned, alive
9 0.3 4 ALCAPA 10/— 12 Weaned, alive
10 16 49 HTx failure 50/— 77 Weaned, alive
11 14 55 DCMP 80/— 120 Weaned with bone marrow
transplant, alive
12 0.5 7 Myocarditis 10/— 41 Weaned, alive
13 0.4 6 Myocarditis 10/— 29 Weaned, alive
14 0.25 4 Noncompaction 10/— 62 Weaned, alive
15 0.05 3.5 Myocarditis 10/— 35 Weaned, alive
16 0.6 8 DCMP 10/— 17 Weaned, early cerebral death
Patients 1 to 5 wereweaned in period I and patients 6 to 16 in period II. Outcome status is presented as ofMarch 1, 2009. Supplemental material is available online.DCMP,Dilated
cardiomyopathy; CAVSD, complete atrioventricular defect; HTx, heart transplant; ALCAPA, anomalous left coronary artery origin from pulmonary artery.
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3303).
Death During Device Use
Significantly fewer patients died while supported by the
device in period II (23, 51%, vs 14, 29%, P ¼ .043). The
main reasons for death in both periods were multiorgan fail-
ure (n¼ 13) and cerebrovascular accident after hemorrhage
or ischemia (n¼ 10, including 1 patient with cerebral dam-
age before VAD implantation). Vasoplegic shock was the
cause of death in 5 cases, and lung failure and sepsis were
the cause of death in 3 cases each. In 2 cases, bleeding after
dislodgment of cannulas (both patients boys with BVADs,
aged 6 and 11 years, 13 and 2 days on support) caused death,
and in 1 case, perforation of the left ventricle during place-
ment of a chest drain (girl aged 16 years with LVAD, 5 days
on support) caused death.
DISCUSSION
The pediatric Berlin Heart EXCOR VAD is the most
widely used long-term system worldwide for the treatment
of children of all ages with heart failure. This report docu-
ments our experience with this system from its introduction
into clinical use through several steps of system changes and
insights concerning system application that our teamworked
out together with the Berlin Heart company. Since the first
experience with a child supported by a Berlin Heart VAD6
and the subsequent development of miniaturized systems
for children and infants (since 1992), substantial changes
have been introduced into clinical decision making and pa-
tient care,9 and modifications have been made to the system
itself. These modifications have led to improved survival620 The Journal of Thoracic and Cardiovascular Surgand, consequently, longer support times in recent years, es-
pecially for neonates and small infants. These advances
have made the Berlin Heart system a fairly mature tool to
treat severe heart failure successfully in this group of pa-
tients. Additionally, increased waiting time for heart trans-
plants has contributed to the prolongation of the time on
mechanical support. Some of our earlier publications have
presented analyses of these developments on the basis of
studies of small numbers of patients9; here, we have focused
on the analysis of our whole experience with almost 100 pa-
tients, the largest number reported in a single-center study.
The Berlin Heart system has proved to be able to keep
children alive to be bridged to transplant during long pe-
riods with good outcome.15 Such a prolonged support
time has allowed a child being treated for malignancy16 to
reach transplantable status by documentation of a suffi-
ciently long tumor-free period to justify listing for heart
transplant. Similarly, transplantable status may be reached
after prolonged support in children with adequate regres-
sion of preoperatively elevated pulmonary vascular resis-
tance.17
Since 1988, close to 9000 operations for congenital heart
defects and more than 150 pediatric transplants have been
performed at our institution. Centrifugal pumps and
ECMO also have their place in our pediatric program, espe-
cially for patients with the potential for fast myocardial re-
covery and expected short-term support.18,19 In contrast to
patients supported with these devices, those with the
Berlin Heart VAD can be mobilized, extubated, and fed
orally, which is advantageous when waiting periods longer
than 3 or 4 weeks must be anticipated.3,20,21 Eight patients
were supported by ECMO before VAD implantation, withery c March 2011
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from ECMO to VAD was taken when it became clear that
longer-term support was needed and the patient had not suf-
fered severe damage, particularly to the brain, before or dur-
ing ECMO. Another indication for VAD implantation was
continuous bleeding on ECMO, because of the lower antico-
agulation required on VAD, in particular in cases of open
ECMO. A switch from ECMO to pediatric Berlin Heart EX-
COR has also been described,22 and the Berlin Heart pediat-
ric system allows children to be bridged to transplant
through long waiting periods.15 In contrast to patients with
ECMO support, thosewith VAD support required less trans-
fusion of blood products, with correspondingly decreased
risks of infection and of development of HLA anti-
bodies.23,24 The advantages of long-term VAD support,
also in terms of a better cost-effectiveness ratio and of the
quality-adjusted life years saved,25 have been recognized,
and an increasing number of centers are now using this
type of support system for children.26-30
Application of theMedosVAD (MEDOSMedizintechnik
AG, Stolberg, Germany), which is also available for small
children, has been reported to be successful with shorter sup-
port times.31 The use of adult-type long-term implantable
LVADs, such as the HeartMate I and II (Thoratec Corpora-
tion, Pleasanton, Calif), Ventracor,32 orMicroMedDeBakey
VAD (MicroMed Cardiovascular, Inc, Houston, Tex), is
limited to children weighing more than 15 to 20 kg.21,33-37
In our series, there were no patients with persistent intra-
cardiac shunts implanted with the Berlin Heart VAD, be-
cause regulation of the pump flow and the patient
circulation, systemic and pulmonary, is extremely difficult.
Such patients were treated with ECMO if needed. There
have been some reports of successful use of the Berlin Heart
EXCORVAD for single-ventricle physiology,38-40 however,
and in some cases with aortopulmonary shunts.38 In chil-
dren who have undergone staged single-ventricle palliation,
including Norwood stage 1 procedure, bidirectional cavo-
pulmonary anastomosis, and repair of obstructed pulmo-
nary veins, the VAD could be used without an oxygenator
while keeping the aortopulmonary shunt open and main-
taining high pump flows. Clipping of the shunt seems to
be unnecessary.41
Aswith any kind of support system,making the decision in
favor of earlier implantation has yielded better results. This
effect was most pronounced among patients younger than 1
year. During the earlier period, most of these patients started
support with the system in a state of advanced circulatory
failure, characterized by irreversible organ shock sequelae
and unresponsiveness of the peripheral circulation to a-stim-
ulants, so-called vasoplegia. Consequently, in period I no pa-
tient younger than 1 year survived for longer than 30 days
after VAD implantation, whereas more than three quarters
of the infants could finally leave the hospital alive after a pol-
icy of earlier placement of the system had been established.The Journal of Thoracic and CaThe introduction into the pediatric field of the criteria that
have become well established in the adult population (VAD
implantation before shock organ failure sets in or, at the
latest, at the very first signs of such organ failure3,42-46)
has fulfilled its promise of better survival. At present, we
adhere to the criteria given in the Methods section,
whereby the speed of deterioration plays an important role.
We strongly believe that, with more confidence in the sys-
tem, these criteriawill beapplied less restrictively in the future.
Increased survival, however, and the fact that more patients
were treated with an LVAD alone, were extubated while
supported by the VAD and did not require delayed sternum
closure, indicates the positive effects of using these criteria.
Earlier decision making for mechanical circulatory sup-
port is most important in the patients after cardiopulmonary
bypass. During period I, in most cases this decision was
made after protracted courses in the intensive care unit, of-
ten after repeated cardiopulmonary resuscitation. There was
only one long-term survivor among the patients supported
by a VAD under these circumstances. Now, with a staged
concept of immediate ECMO installation and later VAD im-
plantation when it becomes apparent that the cardiac func-
tion cannot be stabilized postoperatively, such catastrophic
courses have been avoided. A similar concept is applied
for decompensated chronic heart failure requiring resuscita-
tion. This strategy is evident in the significantly increased
number of patients supported by ECMO before VAD im-
plantation (Table 1). In patients with chronic end-stage heart
failure, measurement of levels of natriuretic peptides and
markers of inflammation offers improved prediction of the
optimal time points for VAD implantation and weaning.47
In our pediatric population, the sex distributions were
similar in the early and late periods. In the adult population,
approximately 80% patients are male.48 This phenomenon
supports the impact of sex on the incidence, diagnosis, and
treatment of heart failure.
Apical drainage has made it more likely that the circula-
tion can be sustained with LVAD support alone, whereas
with atrial drainage, BVAD support more often became in-
evitable. In contrast to our practice, Gandhi and associates27
showed that BVAD support offers an additional means of
improving postoperative course and reversing extremely el-
evated pulmonary vascular resistance and can be used effec-
tively in small children as a bridge to heart transplant, with
low mortality and morbidity.27 Although we now have good
results with the LVAD alone, we primarily use a BVAD in
cases of profound cardiogenic shock or acute rejection and
in such special situations as cases of large cardiac tumors.
Despite significant progress, anticoagulation and its
monitoring remain a major problem.12,24,49-52 Heparin
coating alone has not solved all the problems. In both
periods, pumps had to be exchanged when significant
thrombus formation became visible, although this rate
significantly decreased during period II. In addition, therdiovascular Surgery c Volume 141, Number 3 621
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deficits, calculated per day of support, was reduced by
50% in the later period.
The anticoagulation regimen that we currently use has
been described in detail.9,13,24,53 In 1 particular case, after
a frustrating period during which multiple pump thrombi
were seen despite intravenous unfractionated heparin,
we switched to low–molecular weight heparin with
monitoring of anti-Xa activity. Since then, 3 other children
requiring long-term anticoagulation during VAD support
have been treated with low–molecular weight heparin, al-
lowing a more stable level of anticoagulation without
thromboembolic events. The successful long-term use of
low–molecular weight heparin has already been described,
and it may be a promising alternative to intravenous heparin
in some cases.54,55 The role of new oral anticoagulants also
needs further evaluation.
In contrast to our experience, several groups from the
United States have reported frequent neurologic events. These
authors have recommended that device exchange at the bed-
sidebeconsideredat theearliest visualizationof thrombus for-
mation.26,56 Our current criteria for pump exchange are any
thrombus formation in the left pump or in the left cannulas
and thrombus of more than a few millimeters or free-
floating thrombi of any size in the right pump and cannulas.
The durability of all the currently available VADs is lim-
ited to a number of years. Therefore, in children and young
adults with end-stage heart failure and contraindications
for heart transplant, such as high pulmonary vascular resis-
tance or uncertain freedom from malignancy after tumor
treatment, there are no long-term options available. In these
cases theVADmay bridge children to the status of transplant-
ability, andmore childrenwill require long-term support.16,17
For such long-term support, smaller and implantable devices
would be a better choice in terms of quality of life than extra-
corporeal devices, such as the Berlin Heart EXCOR.
All axial-flow devices available for commercial use in
Europe may be used in older children for long-term support.
Except for a small number of MicroMed DeBakey VAD57
and Ventracor32 implantations, including 1 in a 6-year-old
girl,35 there have been no reports of such cases as yet. We
implanted the axial-flow adult Berlin Heart Incor LVAD
in a 17-year-old adolescent.
The US National Heart, Lung, and Blood Institute is sup-
porting 5 programs for the development of pediatric circu-
latory support devices.58 The devices are expected to be
ready for clinical studies in 2009. Only some of these
pumps, however, such as the Jarvik 2000 for infants (Jarvik
Heart, Inc, New York, NY), have as yet been tested in initial
animal studies.59,60
Limitations
This study is of a retrospective nature and presents the
clinical experience of the center where the system was de-622 The Journal of Thoracic and Cardiovascular Surgveloped and most of the improvements were introduced.
Some aspects of our experience with smaller patient cohorts
have been analyzed and published previously. The long-
term survival and functional status, as well as the cerebral
function and neurodevelopment of the surviving patients,
are currently under investigation and could not be included
here. The study was not designed to directly compare
ECMO and VAD treatments.
CONCLUSIONS
In our experience, earlier implantation of VADs, heparin-
coating of the blood pumps, and substantial modifications in
cannula design, anticoagulation, and the coagulation moni-
toring regimen have led to significant increases in survival
and in discharge rate, especially among children younger
than 1 year and after postcardiotomy heart failure. The pe-
diatric size Berlin Heart EXCORVADnow offers a valuable
option as a bridge to transplant or recovery for children with
cardiogenic shock.
We thank Anne Gale, Editor in the Life Sciences (ELS), for
editorial assistance, and we thank Katharina Hoffmann for support
with data acquisition.
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FIGURE E1. Analysis of cumulative mortality in entire population. Im-
portant changes in ventricular assist device design, patient selection, and
postoperative care are marked in relation to time.
FIGURE E2. Kaplan –Meier analysis for cumulative survival after heart
transplant. There was no difference in survival between groups.HTx,Heart
transplant; BTT, bridge to transplant with ventricular assist device.
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H
DTABLE E1. Diagnoses and surgical procedures in patients with congenital heart defects in end-stage chronic heart failure
Case Diagnosis and procedures Age (y) Weight (kg) Sex Pumps Support (d) Outcome
1 Dilatation of AS, CoA 8 27 M LVAD 7 HTx
2 Dextro TGA, status post-Mustard 13 51 F LVAD 5 Death
3 Status post-AVR 9 35 F BVAD 1 Death
4 PA atresia and coronary sinusoids 6 d 4 M LVAD 2 Death
5 Dextro TGA, status post-Senning 5 18.5 M BVAD 13 Death
6 Status post tetralogy of Fallot correction, status post-homograft implantation 15 25 F BVAD HTx
7 Status post-Fontan 13 21 F LVAD 1 Death
8 TGA, status post-Mustard 52 17 M LVAD 41 Death
9 TGA, status post-Senning 16 47 M LVAD 43 Death
10 Ebstein anomaly 4 18 F BVAD 17 Recovery
11 CAVSD, status post-Fontan 10 24 F LVAD 15 Death
12 VSD, status post-PA banding 0.4 5.4 M LVAD 16 Recovery
13 Single ventricle, truncus arteriosus communis, status post-BDCPA anastomosis 1 9 M LVAD 16 Death
14 AV stenosis, status post-AVR, -MVRep, and -CABG 10 26 M BVAD 43 Death
15 Status postcorrection of HLHS 4 19 M LVAD 26 Death
Patients 1 to 9 were treated in period I and patients 10 to 15 in period II. AS, Aortic stenosis; CoA, coarctation of aorta; M, male; LVA, left ventricular assist device; HTx, heart
transplant; TGA, transposition of the great arteries; F, female; AVR, aortic valve replacement; BVAD, biventricular assist device; PA, pulmonary artery; CAVSD, complete atrio-
ventricular septal defect; VSD, ventricular septal defect; BDCPA, bidirectional caval pulmonary anastomosis;MVRep,mitral valve repair;CABG, coronary artery bypass grafting;
HLHS, hypoplastic left heart syndrome.
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